STOCK TITAN

Boston Scien Cp Stock Price, News & Analysis

BSX NYSE

Welcome to our dedicated page for Boston Scien Cp news (Ticker: BSX), a resource for investors and traders seeking the latest updates and insights on Boston Scien Cp stock.

Boston Scientific Corporation (NYSE: BSX) is a global medical technology company whose news flow reflects activity across cardiovascular, neuromodulation, urology, endoscopy and other therapeutic areas. Company announcements frequently describe new agreements to acquire medical technology firms, clinical and regulatory milestones for key product platforms, and detailed quarterly financial results.

Recent news includes a definitive agreement to acquire Penumbra, Inc. in a cash and stock transaction. Penumbra has developed mechanical thrombectomy and neurovascular devices to treat conditions such as pulmonary embolism, stroke, deep vein thrombosis, acute limb ischemia, heart attack and aneurysms, with products like the Lightning Bolt and Lightning Flash computer assisted vacuum thrombectomy systems and peripheral embolization technologies. Boston Scientific has also announced an agreement to acquire Valencia Technologies Corporation, adding the eCoin implantable tibial nerve stimulation system for urge urinary incontinence, and an agreement to acquire Nalu Medical, Inc., developer of the Nalu Neurostimulation System for peripheral nerve stimulation in chronic pain.

In addition to acquisition news, Boston Scientific regularly issues earnings releases detailing net sales by business and region, growth rates on reported, operational and organic bases, and commentary on segment performance in MedSurg and Cardiovascular. These releases often highlight regulatory approvals, such as expanded labeling for the FARAPULSE Pulsed Field Ablation System or CE marks for devices like the WATCHMAN FLX Pro Left Atrial Appendage Closure Device, as well as clinical study results, including long-term data from deep brain stimulation trials.

Investors and observers following BSX news can also expect updates on investor conferences, investor day events, and governance matters disclosed through press releases and Form 8-K filings. This page aggregates such coverage, offering a centralized view of Boston Scientific’s strategic transactions, product developments, financial updates and corporate announcements over time.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
none

FAQ

What is the current stock price of Boston Scien Cp (BSX)?

The current stock price of Boston Scien Cp (BSX) is $91.2 as of January 20, 2026.

What is the market cap of Boston Scien Cp (BSX)?

The market cap of Boston Scien Cp (BSX) is approximately 130.6B.
Boston Scien Cp

NYSE:BSX

BSX Rankings

BSX Stock Data

130.61B
1.48B
0.19%
93.65%
1.28%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
MARLBOROUGH

BSX RSS Feed